Despite a significant decline in its stock price over the past year, healthcare company Lantheus Holdings (LNTH) continues to firmly occupy a top-three position in the portfolio of investment firm Brigade Capital Management. The fund opted to further increase its holdings in the third quarter, underscoring its confidence in this company, which consistently generates robust cash flow and is quietly reshaping its growth engine.
According to documents disclosed by the U.S. Securities and Exchange Commission (SEC) on November 14, New York-based Brigade Capital Management increased its holdings in Lantheus Holdings by 173,200 shares in the third quarter. This move added approximately $4.51 million to the value of its holdings, bringing the total value to about $16.23 million by the end of the quarter. Based on the fund’s approximately $815.2 million in assets under management, Lantheus now accounts for about 2.0% of the portfolio and has risen to become its third-largest holding, behind only Nabors Industries (NBR) and Lumen Technologies (LUMN). This increase in holdings is particularly noteworthy given that it occurred against the backdrop of LNTH’s stock price falling 27% over the past year, significantly underperforming the S&P 500 Index, which rose 15% during the same period.
Lantheus Holdings is a company focused on advanced diagnostic and therapeutic products in the cardiovascular and oncology fields. Its product portfolio includes DEFINITY, an ultrasound imaging agent; PYLARIFY, a prostate cancer imaging agent; and AZEDRA, a radiotherapy agent. The company generates revenue primarily by selling these specialized products to hospitals, clinics, and distribution networks worldwide. Despite facing stock price pressure, the company’s fundamentals remain resilient. Its third-quarter earnings report revealed revenue of $384 million and free cash flow of nearly $95 million. Although GAAP profits declined due to acquisition costs, increased operating expenses, and year-over-year fluctuations in the performance of its flagship product, PYLARIFY, the company maintained profitability and ample cash flow.
During the period of weak stock performance, Lantheus’s management has continued to advance its strategic initiatives. During the quarter, the company completed the acquisition of Life Molecular Imaging to expand its product pipeline and research and development capabilities. At the same time, it actively returned value to shareholders by repurchasing $100 million worth of its stock and reaffirmed its full-year guidance, which includes revenue of approximately $1.5 billion and adjusted earnings per share exceeding $5.50. These actions indicate that the company is leveraging its solid financial foundation to prepare for long-term growth while reinforcing its market position in the diagnostics field.
Currently, Lantheus is positioned alongside some cyclical or transitioning companies in investment portfolios, suggesting that investors may tolerate a certain degree of stock price volatility given its ample cash flow and strategic flexibility. Its valuation is not as high as that of high-growth stocks, but the company continues to fund the expansion of its product line, the consolidation of its market position, and capital returns. If the company can steadily execute its strategic plans, the current market skepticism may prove to be only temporary. Institutions often choose to increase their holdings after significant stock price declines based on their assessment of a disconnect between intrinsic value and market pricing—a scenario that Lantheus currently finds itself in.
